Loading…
Transchem (BSE 500422)₹417.50−0.38%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Transchem reported sales of ₹0.94 Cr and net profit of ₹2.04 Cr, up 204.5% year on year. For the year to Mar 2026, sales were ₹0 Cr and net profit ₹4.29 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Sep 2025 | Jun 2026 | Sep 2026 | |
|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.94 |
| Expenses | 0.74 | 0.71 | 2.13 |
| Operating Profit | −0.76 | −0.71 | −1.20 |
| OPM % | — | — | −128.0% |
| Other Income | 1.67 | 5.09 | 4.13 |
| Interest | 0.00 | 0.02 | 0.03 |
| Depreciation | 0.00 | 0.04 | 0.06 |
| Profit before tax | 0.94 | 4.34 | 2.85 |
| Tax % | 28.0% | 21.4% | 28.4% |
| Net Profit | 0.67 | 3.43 | 2.04 |
| EPS (Rs) | 0.55 | 2.78 | 1.66 |
| Mar 2026 | |
|---|---|
| Sales | 0.00 |
| Expenses | 3.63 |
| Operating Profit | −3.65 |
| Other Income | 9.22 |
| Interest | 0.00 |
| Depreciation | 0.00 |
| Profit before tax | 5.60 |
| Tax % | 23.6% |
| Net Profit | 4.29 |
| EPS (Rs) | 3.50 |
| Dividend payout % | 0.0% |
For the Sep 2026 quarter, Transchem reported sales of ₹0.94 Cr and net profit of ₹2.04 Cr, up 204.5% year on year. The operating margin was −128.0%.
Transchem's sales for the year to Mar 2026 were ₹0 Cr.
Net profit for the year to Mar 2026 was ₹4.29 Cr. Earnings per share over the same trailing period were ₹3.50.